Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Authors
Majem, M.Forster, M. D.
Krebs, Matthew G
Peguero, J.
Clay, T. D.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. D.
Bajaj, P.
Mueller, C.
Triebel, F.
Affiliation
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainIssue Date
2023
Metadata
Show full item recordCitation
Majem M, Forster MD, Krebs MG, Peguero J, Clay TD, Felip E, et al. Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. Journal of Thoracic Oncology. 2023 Apr;18(4):S43-S4. PubMed PMID: WOS:000995007600012.Journal
Journal of Thoracic OncologyDOI
10.1016/S1556-0864(23)00265-4Additional Links
https://dx.doi.org/10.1016/S1556-0864(23)00265-4Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S1556-0864(23)00265-4